Developer docs
API playgroundTry for free, no card

Search company profiles

Curaleaf Laboratories

Full company profile

uuid00482wa

Namestring
Curaleaf Laboratories
Legal namestring
Rokshaw Ltd
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSunderland, United Kingdom
HQ citystring
Sunderland
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis manufacturing, EU-GMP pharmaceuticals, cannabis-based medicinal products, specials medicines manufacturing, pharmaceutical wholesale distribution
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medical Cannabis Pharmaceutical Manufacturing
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Cannabis Product Manufacturing & Distribution
TypeTransaction Fee
Description

Manufacture and distribution of EU-GMP medical cannabis products to specialist clinics, pharmacies, and healthcare professionals across the UK. Products include dried flowers, oils, pastilles, vape cartridges, suppositories, pessaries, and inhalation devices. B2B revenue model supplying prescription medicines to the growing UK medical cannabis market.

curaleaflaboratories.co.uk
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Curaleaf Laboratories manufactures and distributes EU-GMP cannabis-based medicinal products (CBPMs) at its MHRA-approved facility in Sunderland, UK. The product portfolio includes dried flowers, oils, pastilles, liquid vape cartridges, suppositories, pessaries, and the proprietary Curaleaf Que Medical Inhalation Device (QMID). Products are sold wholesale to specialist clinics, community pharmacies, and healthcare professionals under B2B partnership schemes including the Prescribing Programme, Pharmacy Partnership Scheme, and Manufacturing and Distribution Service.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 99% next-day delivery rate for wholesale and pharmacy customers (orders before 2:30pm)
+2 more records
Product overview1 text field

Curaleaf Laboratories is a UK-based manufacturer and distributor of EU-GMP medical cannabis products, operating as part of Curaleaf International (subsidiary of Curaleaf Holdings). The company offers a portfolio of pharmaceutical-grade medical cannabis products including Dried Flowers, Oils, Pastilles, Liquid Vape Cartridges, Suppositories, and Pessaries. Their flagship innovation is the Curaleaf Que Medical Inhalation Device (QMID) - the first CE-certified liquid inhaler for cannabis-based medicines. The company provides manufacturer and distribution services for producers (Manufacturing and Distribution Service), prescribers (Curaleaf Prescribing Programme), and pharmacies (Pharmacy Partnership Scheme), alongside their own clinical (Curaleaf Clinic) and pharmacy (Curaleaf Pharmacy) operations. The vertically integrated supply chain spans cultivation at Terra Verde in Portugal, extraction at Medalchemy in Spain, and UK-based manufacturing at their Sunderland facility.

Product and service8 records
1Dried Flowers
CategoryCore Product
Description

EU-GMP medical cannabis dried flower products manufactured for prescription use by specialist doctors and clinics across the UK. Part of the core Curaleaf range of UK-manufactured medical cannabis products.

2Oils
CategoryCore Product
Description

Full spectrum medical cannabis oils manufactured to EU-GMP standards, providing consistent dosing for patients prescribed cannabis-based medicinal products by specialist UK clinicians.

3Pastilles
CategoryCore Product
Description

Medical cannabis pastilles — a novel oral dosage form pioneered by Curaleaf Laboratories as an alternative to oils and dried flowers for prescribed patients.

4Liquid Vape Cartridges
CategoryCore Product
Description

Liquid vape cartridges for inhalation delivery of medical cannabis, available in 0.5mL and 1.0mL sizes for use with the QMID inhaler device. Part of the comprehensive EU-GMP product range.

5Medical Cannabis Suppositories and Pessaries
CategoryCore Product
Description

Pioneering medical cannabis suppositories and pessaries — first licensed UK-manufactured dosage forms of this type, designed for specialist prescribers treating patients who may not benefit from traditional administration methods.

6Curaleaf Que Medical Inhalation Device (QMID)
CategoryMedical Device
Description

CE-certified EU Class IIa liquid inhaler device for precise, standardized timed dosing of cannabis-based medicines. Features inhalation activation, reusable hardware, and replaceable 0.5mL and 1.0mL cartridges. First certified liquid medical cannabis inhaler in the UK.

7Manufacturing and Distribution Service
CategoryB2B Service
Description

B2B contract manufacturing and distribution service for medical cannabis producers seeking to enter or expand in the UK market. Provides MHRA-approved manufacturing, quality assurance, and established UK distribution under partner brands or Curaleaf-owned ranges.

8Curaleaf Formulary
CategoryService Programme
Description

Comprehensive product formulary for healthcare professionals covering the widest variety of EU-GMP UK-manufactured medical cannabis formulations and dosage forms, providing specialist prescribers with a single trusted source for prescribing decisions.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Herdade das Barrocas (HDB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Strategic partnership to reintroduce HDB products to the UK medical cannabis market. Combines Herdade das Barrocas' cultivation capabilities in Portugal with Curaleaf Laboratories' MHRA-approved manufacturing, quality assurance and distribution infrastructure. Cannabis flower cultivated by HDB supplied to Curaleaf for UK manufacturing, packaging and distribution. Initial product availability expected from June 2026.

curaleaflaboratories.co.uk
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Partnership to develop, manufacture, and commercialize innovative medical cannabis products tailored to UK patients and healthcare professionals. Curaleaf leverages MHRA-approved infrastructure and compliance framework while Sanity Group contributes pharmaceutical know-how, intellectual property and experience in cannabinoid-based therapeutics. First products expected available from Q1 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Partnership to manufacture and distribute ANTG's range of pharmaceutical-grade medicinal cannabis products across the UK. Combines Curaleaf's state-of-the-art UK manufacturing capabilities and established distribution network with ANTG's expertise in cultivating and developing consistent cannabis formulations. First products available on prescription from November 2025.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-09-01
Description

Developed the Curaleaf Que Medical Inhalation Device (QMID) in partnership with Jupiter Research. Jupiter's intellectual property and device development expertise combined with Curaleaf's pharmaceutical manufacturing capabilities to create first CE-certified liquid inhaler for cannabis-based medicines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Partnership to exclusively manufacture and distribute medical cannabis API from Dalgety's UK cultivation facility. Dalgety is the first domestic cultivator with EU-GMP licenses for cultivation and supply of medical cannabis products. Full UK vertical supply chain from cultivation to distribution while maintaining EU-GMP standards. Dalgety's 30,000+ sq ft indoor facility features AI-controlled environmental management and precision hydroponic cultivation.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2024-01-01
Description

Gold education partner providing CPD-accredited cannabis education to healthcare professionals. Delivers educational content, webinars, surveys, roundtables and clinical resources. Supports recruitment and education of new prescribers entering the medical cannabis space.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Part of Curaleaf International vertical supply chain. Terra Verde holds the second oldest cultivation licence in Europe with 2.8 hectares of indoor greenhouse cultivation. Pioneer in plant-based research, genetics and production of consistent, natural and high-quality medicinal cannabis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Part of Curaleaf International vertical supply chain. Medalchemy is a leading research laboratory and manufacturing facility in Spain, GMP certified since 2013 with a decade of experience in research, development and manufacture of active pharmaceutical ingredients (APIs). First laboratory in Spain to receive a licence to manufacture and export cannabis oils.

Strategic tierMinorTypeOthers
Description

Educational partnership supporting creation of highly skilled scientific and pharmaceutical jobs in the North East of England while raising awareness of medical cannabis as a growing healthcare sector.

Strategic tierMinorTypeOthers
Description

Educational partnership supporting skills development and awareness of medical cannabis as a rapidly growing healthcare sector in the UK.

Strategic tierCoreTypeOthers
Description

Curaleaf Laboratories is part of Curaleaf International, which is a subsidiary of Curaleaf Holdings Inc., the largest cannabis company in the world. Provides access to global supply and distribution partnerships throughout Europe and the UK.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

Large international medical and recreational cannabis producer with EU-GMP certified facilities; a broad incumbent whose EU-produced CBPMs compete with Curaleaf's UK-manufactured portfolio across European distribution.

TypeBroad incumbent
Description

Originator of Epidiolex and historically the dominant UK-based cannabis-derived pharmaceutical company; now part of Jazz Pharmaceuticals. A broad incumbent whose cannabinoid pharma capabilities and UK regulatory heritage inform the benchmark Curaleaf operates against.

3Sativa Investments
TypeOthers
Description

UK-listed cannabis investment and operating platform covering cultivation, manufacturing, and clinic exposure; ecosystem participant and capital-markets vehicle relevant to the broader UK medical cannabis sector Curaleaf serves.

TypeDirect peer
Description

UK-based MHRA-licensed medical cannabis cultivator and manufacturer focused on EU-GMP active pharmaceutical ingredients and finished CBPMs — directly competes with Curaleaf's Sunderland manufacturing and UK supply chain.

TypeDirect peer
Description

UK medical cannabis operator spanning specialist clinics, pharmacy dispensing, and product supply through its proprietary formulary — overlaps with Curaleaf's Clinic, Pharmacy, and Prescribing Programme ecosystem.

TypeDirect peer
Description

UK-based MHRA-licensed manufacturer and distributor of medical cannabis products, operating a vertically integrated model targeting specialist clinics and pharmacies — the closest direct competitor to Curaleaf Laboratories in the UK CBPM market.

7EMMAC Life Sciences
TypeEmerging player
Description

European medical cannabis operator with cultivation and manufacturing across multiple EU jurisdictions — an emerging player with overlapping EU-GMP supply that competes for UK distribution partnerships and producer-to-UK pathways.

8Kanabo
TypeDirect peer
Description

Israel- and UK-focused medical cannabis company with proprietary inhalation device technology (similar device-led differentiation to Curaleaf's QMID) and growing UK pharmacy distribution — directly comparable on product format and route-to-market.

TypeEmerging player
Description

Vertically integrated medical cannabis company with EU operations and a clinical-services-led UK distribution approach — an emerging player with adjacent go-to-market overlap on clinics and patient access.

10Tilray Brands
TypeBroad incumbent
Description

Global cannabis incumbent with EU-GMP manufacturing footprint and existing UK medical cannabis imports — competes broadly with Curaleaf in the UK supply market and has the scale to challenge on price and product breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curaleaf Laboratories

Medical Cannabis Pharmaceutical Manufacturingcuraleaflaboratories.co.uk

Curaleaf Laboratories firmographics

Firmographics
Name
Curaleaf Laboratories
Legal name
Rokshaw Ltd
Website
https://curaleaflaboratories.co.uk
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Where Curaleaf Laboratories is headquartered

Location

Headquarters

HQ city
Sunderland
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Curaleaf Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Cannabis Product Manufacturing & Distribution: Manufacture and distribution of EU-GMP medical cannabis products to specialist clinics, pharmacies, and healthcare professionals across the UK. Products include dried flowers, oils, pastilles, vape cartridges, suppositories, pessaries, and inhalation devices. B2B revenue model supplying prescription medicines to the growing UK medical cannabis market.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Curaleaf Laboratories product offering

Product offering

Core offering

Curaleaf Laboratories manufactures and distributes EU-GMP cannabis-based medicinal products (CBPMs) at its MHRA-approved facility in Sunderland, UK. The product portfolio includes dried flowers, oils, pastilles, liquid vape cartridges, suppositories, pessaries, and the proprietary Curaleaf Que Medical Inhalation Device (QMID). Products are sold wholesale to specialist clinics, community pharmacies, and healthcare professionals under B2B partnership schemes including the Prescribing Programme, Pharmacy Partnership Scheme, and Manufacturing and Distribution Service.

Product overview

Curaleaf Laboratories is a UK-based manufacturer and distributor of EU-GMP medical cannabis products, operating as part of Curaleaf International (subsidiary of Curaleaf Holdings). The company offers a portfolio of pharmaceutical-grade medical cannabis products including Dried Flowers, Oils, Pastilles, Liquid Vape Cartridges, Suppositories, and Pessaries. Their flagship innovation is the Curaleaf Que Medical Inhalation Device (QMID) - the first CE-certified liquid inhaler for cannabis-based medicines. The company provides manufacturer and distribution services for producers (Manufacturing and Distribution Service), prescribers (Curaleaf Prescribing Programme), and pharmacies (Pharmacy Partnership Scheme), alongside their own clinical (Curaleaf Clinic) and pharmacy (Curaleaf Pharmacy) operations. The vertically integrated supply chain spans cultivation at Terra Verde in Portugal, extraction at Medalchemy in Spain, and UK-based manufacturing at their Sunderland facility.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dried Flowers EU-GMP medical cannabis dried flower products manufactured for prescription use by specialist doctors and clinics across the UK. Part of the core Curaleaf range of UK-manufactured medical cannabis products.
  • Oils Full spectrum medical cannabis oils manufactured to EU-GMP standards, providing consistent dosing for patients prescribed cannabis-based medicinal products by specialist UK clinicians.
  • Pastilles Medical cannabis pastilles — a novel oral dosage form pioneered by Curaleaf Laboratories as an alternative to oils and dried flowers for prescribed patients.
  • Liquid Vape Cartridges Liquid vape cartridges for inhalation delivery of medical cannabis, available in 0.5mL and 1.0mL sizes for use with the QMID inhaler device. Part of the comprehensive EU-GMP product range.
  • Medical Cannabis Suppositories and Pessaries Pioneering medical cannabis suppositories and pessaries — first licensed UK-manufactured dosage forms of this type, designed for specialist prescribers treating patients who may not benefit from traditional administration methods.
  • Curaleaf Que Medical Inhalation Device (QMID) CE-certified EU Class IIa liquid inhaler device for precise, standardized timed dosing of cannabis-based medicines. Features inhalation activation, reusable hardware, and replaceable 0.5mL and 1.0mL cartridges. First certified liquid medical cannabis inhaler in the UK.
  • Manufacturing and Distribution Service B2B contract manufacturing and distribution service for medical cannabis producers seeking to enter or expand in the UK market. Provides MHRA-approved manufacturing, quality assurance, and established UK distribution under partner brands or Curaleaf-owned ranges.
  • Curaleaf Formulary Comprehensive product formulary for healthcare professionals covering the widest variety of EU-GMP UK-manufactured medical cannabis formulations and dosage forms, providing specialist prescribers with a single trusted source for prescribing decisions.

Quantifiable outcome

  • 99% next-day delivery rate for wholesale and pharmacy customers (orders before 2:30pm)
  • +2 more outcomes

Companies that use Curaleaf Laboratories

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

Curaleaf Laboratories technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Curaleaf Laboratories partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, strategic and minor.

  • Herdade das Barrocas (HDB)coreStrategic or Co-development Partner · 22 June 2026Strategic partnership to reintroduce HDB products to the UK medical cannabis market. Combines Herdade das Barrocas' cultivation capabilities in Portugal with Curaleaf Laboratories' MHRA-approved manufacturing, quality assurance and distribution infrastructure. Cannabis flower cultivated by HDB supplied to Curaleaf for UK manufacturing, packaging and distribution. Initial product availability expected from June 2026.
  • Sanity GroupcoreStrategic or Co-development Partner · 26 February 2026Partnership to develop, manufacture, and commercialize innovative medical cannabis products tailored to UK patients and healthcare professionals. Curaleaf leverages MHRA-approved infrastructure and compliance framework while Sanity Group contributes pharmaceutical know-how, intellectual property and experience in cannabinoid-based therapeutics. First products expected available from Q1 2026.
  • Australian Natural Therapeutics Group (ANTG)coreStrategic or Co-development Partner · 12 November 2025Partnership to manufacture and distribute ANTG's range of pharmaceutical-grade medicinal cannabis products across the UK. Combines Curaleaf's state-of-the-art UK manufacturing capabilities and established distribution network with ANTG's expertise in cultivating and developing consistent cannabis formulations. First products available on prescription from November 2025.
  • Jupiter Research LLC (TILT Holdings)strategicTechnology or Integration · 1 September 2025Developed the Curaleaf Que Medical Inhalation Device (QMID) in partnership with Jupiter Research. Jupiter's intellectual property and device development expertise combined with Curaleaf's pharmaceutical manufacturing capabilities to create first CE-certified liquid inhaler for cannabis-based medicines.
  • Dalgety LtdcoreStrategic or Co-development Partner · 1 January 2024Partnership to exclusively manufacture and distribute medical cannabis API from Dalgety's UK cultivation facility. Dalgety is the first domestic cultivator with EU-GMP licenses for cultivation and supply of medical cannabis products. Full UK vertical supply chain from cultivation to distribution while maintaining EU-GMP standards. Dalgety's 30,000+ sq ft indoor facility features AI-controlled environmental management and precision hydroponic cultivation.
  • Medical Cannabis Clinicians Society (MCCS)coreGTM or Marketing Partner · 1 January 2024Gold education partner providing CPD-accredited cannabis education to healthcare professionals. Delivers educational content, webinars, surveys, roundtables and clinical resources. Supports recruitment and education of new prescribers entering the medical cannabis space.
  • Terra Verde (Portugal)coreStrategic or Co-development Partner · 1 January 2019Part of Curaleaf International vertical supply chain. Terra Verde holds the second oldest cultivation licence in Europe with 2.8 hectares of indoor greenhouse cultivation. Pioneer in plant-based research, genetics and production of consistent, natural and high-quality medicinal cannabis.
  • Medalchemy (Spain)coreStrategic or Co-development Partner · 1 January 2019Part of Curaleaf International vertical supply chain. Medalchemy is a leading research laboratory and manufacturing facility in Spain, GMP certified since 2013 with a decade of experience in research, development and manufacture of active pharmaceutical ingredients (APIs). First laboratory in Spain to receive a licence to manufacture and export cannabis oils.
  • Sunderland CollegeminorOthersEducational partnership supporting creation of highly skilled scientific and pharmaceutical jobs in the North East of England while raising awareness of medical cannabis as a growing healthcare sector.
  • University of SunderlandminorOthersEducational partnership supporting skills development and awareness of medical cannabis as a rapidly growing healthcare sector in the UK.
  • Curaleaf InternationalcoreOthersCuraleaf Laboratories is part of Curaleaf International, which is a subsidiary of Curaleaf Holdings Inc., the largest cannabis company in the world. Provides access to global supply and distribution partnerships throughout Europe and the UK.

Scale indicators4 records

Recent moves8 records

Curaleaf Laboratories competitors and assessment

Company assessment

Broad incumbents

  • Aurora Cannabis: Large international medical and recreational cannabis producer with EU-GMP certified facilities; a broad incumbent whose EU-produced CBPMs compete with Curaleaf's UK-manufactured portfolio across European distribution.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): Originator of Epidiolex and historically the dominant UK-based cannabis-derived pharmaceutical company; now part of Jazz Pharmaceuticals. A broad incumbent whose cannabinoid pharma capabilities and UK regulatory heritage inform the benchmark Curaleaf operates against.
  • Tilray Brands: Global cannabis incumbent with EU-GMP manufacturing footprint and existing UK medical cannabis imports — competes broadly with Curaleaf in the UK supply market and has the scale to challenge on price and product breadth.

Others

  • Sativa Investments: UK-listed cannabis investment and operating platform covering cultivation, manufacturing, and clinic exposure; ecosystem participant and capital-markets vehicle relevant to the broader UK medical cannabis sector Curaleaf serves.

Direct peers

  • Celadon Pharmaceuticals: UK-based MHRA-licensed medical cannabis cultivator and manufacturer focused on EU-GMP active pharmaceutical ingredients and finished CBPMs — directly competes with Curaleaf's Sunderland manufacturing and UK supply chain.
  • Lyphe Group: UK medical cannabis operator spanning specialist clinics, pharmacy dispensing, and product supply through its proprietary formulary — overlaps with Curaleaf's Clinic, Pharmacy, and Prescribing Programme ecosystem.
  • Grow Pharma: UK-based MHRA-licensed manufacturer and distributor of medical cannabis products, operating a vertically integrated model targeting specialist clinics and pharmacies — the closest direct competitor to Curaleaf Laboratories in the UK CBPM market.
  • Kanabo: Israel- and UK-focused medical cannabis company with proprietary inhalation device technology (similar device-led differentiation to Curaleaf's QMID) and growing UK pharmacy distribution — directly comparable on product format and route-to-market.

Emerging players

  • EMMAC Life Sciences: European medical cannabis operator with cultivation and manufacturing across multiple EU jurisdictions — an emerging player with overlapping EU-GMP supply that competes for UK distribution partnerships and producer-to-UK pathways.
  • Khiron Life Sciences: Vertically integrated medical cannabis company with EU operations and a clinical-services-led UK distribution approach — an emerging player with adjacent go-to-market overlap on clinics and patient access.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Curaleaf Laboratories social profiles

Digital presence

Curaleaf Laboratories compliance and trust

Trust signal

Compliance5 records

Curaleaf Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curaleaf Laboratories leadership team

Management profile

Number of profiles

Profiles3 records

Curaleaf Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curaleaf Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curaleaf Laboratories

What does Curaleaf Laboratories do?

Curaleaf Laboratories manufactures and distributes EU-GMP cannabis-based medicinal products (CBPMs) at its MHRA-approved facility in Sunderland, UK. The product portfolio includes dried flowers, oils, pastilles, liquid vape cartridges, suppositories, pessaries, and the proprietary Curaleaf Que Medical Inhalation Device (QMID). Products are sold wholesale to specialist clinics, community pharmacies, and healthcare professionals under B2B partnership schemes including the Prescribing Programme, Pharmacy Partnership Scheme, and Manufacturing and Distribution Service.

Is Curaleaf Laboratories a public or private company?

Curaleaf Laboratories is a private company. It is classified as corporate owned and is currently operating.

When was Curaleaf Laboratories founded?

Curaleaf Laboratories was founded in 2012. It employs 51 to 100 people.

Where is Curaleaf Laboratories based?

Curaleaf Laboratories is headquartered in Sunderland, United Kingdom, in the Europe region.

How does Curaleaf Laboratories make money?

One revenue line is on record: medical Cannabis Product Manufacturing & Distribution.

Who are Curaleaf Laboratories's main competitors?

Broad incumbents on record are Aurora Cannabis, GW Pharmaceuticals (Jazz Pharmaceuticals) and Tilray Brands. Sativa Investments is listed as an others. Direct peers are Celadon Pharmaceuticals, Lyphe Group, Grow Pharma and Kanabo. Emerging players are EMMAC Life Sciences and Khiron Life Sciences.

Does Curaleaf Laboratories have an API?

No public API is recorded for Curaleaf Laboratories.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals